References
- Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P. 2016. Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos. 44(8):1201–1212.
- Guo Y, Ahn M-J, Chan A, Wang C-H, Kang J-H, Kim S-B, Bello M, Arora RS, Zhang Q, He X, et al. 2019. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Ann Oncol. 30(11):1831–1839.
- Han L, Zhang X, Wang Z, et al. 2021. SH-1028, an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Front Pharmacol. 12:665253.
- Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, et al. 2019. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: a pooled subgroup analysis. Cancer Sci. 110(9):2884–2893.
- Hoogenboom N, Demont D, de Zwart E, Verkaik S, Emmelot M, van de Kar B, Kaptein A, Barf T. 2021. Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors. Bioorg Med Chem Lett. 52:128406.
- Hsu C-C, Liao B-C, Liao W-Y, Markovets A, Stetson D, Thress K, Yang JC-H. 2020. Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer. J Thorac Oncol. 15(1):50–61.
- Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, Ahn M-J, Kim S-W, Su W-C, Horn L, et al. 2015. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 372(18):1689–1699.
- Li Y, Xu Y, Wu X, He C, Liu Q, Wang F. 2019. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients. J Thorac Dis. 11(7):3004–3014.
- Mitchell R, Bailey C, Ewles M, Swan G, Turpin P. 2019. Determination of osimertinib in human plasma, urine and cerebrospinal fluid. Bioanalysis. 11(10):987–1001.
- Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WSME, et al. 2017. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 376(7):629–640.
- O’Kane GM, Liu G, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, et al. 2019. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. Lung Cancer. 131:86–89.
- Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. 2018. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29(suppl_1):i10–i19.
- Xiong A, Ren S, Liu H, Miao L, Wang L, Chen J, Li W, Li R, Wang X, Lu Z, et al. 2022. Efficacy and safety of SH-1028 in patients with EGFR T790M-positive NSCLC: a multicenter, single-arm, open-label, phase 2 trial. J Thorac Oncol. 17(10):1216–1226.
- Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ, et al. 2013. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 19(8):2240–2247.
- Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong K-K, Meyerson M, Eck MJ. 2008. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 105(6):2070–2075.
- Zhao B, Xiao Z, Qi J, Luo R, Lan Z, Zhang Y, Hu X, Tang Q, Zheng P, Xu S, et al. 2019. Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. Eur J Med Chem. 163:367–380.